Abstract:The human microbiota is fundamental to correct immune system development and balance. Dysbiosis, or microbial content alteration in the gut and respiratory tract, is associated with immune system dysfunction and lung disease development. The microbiota's influence on human health and disease is exerted through the abundance of metabolites produced by resident microorganisms, where short-chain fatty acids (SCFAs) represent the fundamental class. SCFAs are mainly produced by the gut microbiota through anaerobic fermentation of dietary fibers, and are known to influence the homeostasis, susceptibility to and outcome of many lung diseases. This article explores the microbial species found in healthy human gastrointestinal and respiratory tracts. We investigate factors contributing to dysbiosis in lung illness, and the gut-lung axis and its association with lung diseases, with a particular focus on the functions and mechanistic roles of SCFAs in these processes. The key focus of this review is a discussion of the main metabolites of the intestinal microbiota that contribute to host-pathogen interactions: SCFAs, which are formed by anaerobic fermentation. These metabolites include propionate, acetate, and butyrate, and are crucial for the preservation of immune homeostasis. Evidence suggests that SCFAs prevent infections by directly affecting host immune signaling. This review covers the various and intricate ways through which SCFAs affect the immune system's response to infections, with a focus on pulmonary diseases including chronic obstructive pulmonary diseases, asthma, lung cystic fibrosis, and tuberculosis. The findings reviewed suggest that the immunological state of the lung may be indirectly influenced by elements produced by the gut microbiota. SCFAs represent valuable potential therapeutic candidates in this context.

Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases

Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis—A Potential Therapeutic Intervention to Improve Lung Health

Possible role of gut microbes and host’s immune response in gut–lung homeostasis

Short-chain fatty acids as a potential treatment for infections: a closer look at the lungs

The Influence of the Gut Microbiota on Host Health: A Focus on the Gut–Lung Axis and Therapeutic Approaches

Lung microbiota and potential treatment of respiratory diseases

Diet, Microbiota and Gut-Lung Connection

Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics

Role of Short-Chain Fatty Acids Produced by Gut Microbiota in Innate Lung Immunity and Pathogenesis of the Heterogeneous Course of Chronic Obstructive Pulmonary Disease

Gut microbiome a promising target for management of respiratory diseases

Microbiome effects on immunity, health and disease in the lung

Butyrate: Connecting the gut-lung axis to the management of pulmonary disorders

Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment

Gut microbiota derived short-chain fatty acids in physiology and pathology: An update

Role of Lung Microbiome in Innate Immune Response Associated With Chronic Lung Diseases

Gut microbiota dysbiosis and its impact on asthma and other lung diseases: potential therapeutic approaches

Lung Immune Tone via Gut-Lung Axis: Gut-derived LPS and Short-chain Fatty Acids' immunometabolic regulation of Lung IL-1β, FFAR2 and FFAR3 Expression.

The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections

Short-chain fatty acids: linking diet, the microbiome and immunity

COPD and Gut–Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics